1-4 of 4
Fulya Korkmaz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Characterization of a Human Bone Marrow-Derived CRISPR/Cas9 Cell Model for Chronic Myeloid Leukemia

Pia Christin Radszuweit, Barbara Mankel, Fulya Korkmaz, Hildegard Keppeler, Claudia Lengerke, Dominik Schneidawind, Corina Schneidawind
Journal: Blood
Blood (2024) 144 (Supplement 1): 1353.
https://doi.org/10.1182/blood-2024-209947
Published: 2024
Journal Articles

Induction of t(9;22) (q34;q11) in Bone Marrow-Derived HSPCs Via CRISPR/Cas9 to Reveal the Differences of the Leukemogenic Properties of p210 BCR/ABL1 and p185 BCR/ABL1

Pia Radszuweit, Fulya Korkmaz, Barbara Mankel, Rahel Fitzel, Estelle Erkner, Hildegard Keppeler, Claudia Lengerke, Dominik Schneidawind, Corina Schneidawind
Journal: Blood
Blood (2022) 140 (Supplement 1): 5879.
https://doi.org/10.1182/blood-2022-169414
Published: 2022
Journal Articles

Different MLL Breakpoints Influence Leukemia Characteristics of MLL -Rearranged Cells in a Human CRISPR/Cas9-Based Model

Rahel Fitzel, Sarah Brüstl, Fulya Korkmaz, Barbara Mankel, Estelle Erkner, Hildegard Keppeler, Claudia Lengerke, Dominik Schneidawind, Corina Schneidawind
Journal: Blood
Blood (2022) 140 (Supplement 1): 5857.
https://doi.org/10.1182/blood-2022-169461
Published: 2022
Journal Articles

The Rorɣ/SREBP2 Pathway Is a Master Regulator of Cholesterol Metabolism and Serves As Potential Therapeutic Target in T(4;11) Leukemia

Estelle Erkner, Thomas Hentrich, Rahel Fitzel, Hildegard Keppeler, Fulya Korkmaz, Johan Jeong, Julia Schulze-Hentrich, Claudia Lengerke, Dominik Schneidawind, Corina Schneidawind
Journal: Blood
Blood (2022) 140 (Supplement 1): 2999–3000.
https://doi.org/10.1182/blood-2022-169267
Published: 2022